Anodyne Nanotech key facts
as of Oct 2026- Developer of transdermal drug delivery technology designed to reformulate clinically validated molecules into needle-free therapeutics for chronic diseases.
- Anodyne Nanotech is valued at approximately $7.0M as of Oct 2026 (last reported valuation).
- It has raised $9.6M across 3 recorded rounds; the latest was Early Stage VC ($12.6M) in May 2026.
- Notable investors include Bantam Group, Endeavor Greece, Big Pi Ventures, New Ventures Pitch Competition, Relativity Healthcare Partners — 7 tracked in total.
- Anodyne Nanotech has filed 3 Form Ds with the SEC since 2020, most recently May 2021 ($2.0M sold to 15 investors).
- Status: Privately Held (backing).
Anodyne Nanotech's last reported valuation, Aug 2020. Nothing priced has surfaced since.
- ·Watch Anodyne Nanotech: the Monday email on marks, rounds and moves
Anodyne Nanotech funding rounds
3 roundsAnodyne Nanotech valuation
Anodyne Nanotech's last reported valuation was $7 million in Aug 2020. No priced round, secondary trade or fund mark has surfaced since.
How much has Anodyne Nanotech raised?
Anodyne Nanotech has raised $9.6 million across 3 recorded rounds since 2020. The largest was a $2 million debt round in Feb 2021; the most recent was a $12.6 million early-stage round in May 2026.
Anodyne Nanotech has filed 3 Form Ds with the SEC since 2020, most recently in May 2021 ($2 million sold to 15 investors).
Anodyne Nanotech investors
7 investors are on record for Anodyne Nanotech, including Bantam Group, Endeavor Greece, Big Pi Ventures and New Ventures Pitch Competition. The early-stage round in May 2026 drew 47 investors.
About Anodyne Nanotech
Developer of transdermal drug delivery technology designed to reformulate clinically validated molecules into needle-free therapeutics for chronic diseases. The company offers a patch-based platform licensed from Tufts University capable of delivering multi-milligram doses of biologics, enabling patients with obesity and related conditions to access alternatives to injectables and infusions while expanding treatment possibilities through combination therapies.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2019
- Employees
- 20
- Website
- theheropatch.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.